March 24, 2026/
World Tuberculosis Day 2026 – "Yes! We Can End TB: Led by Countries, Powered by People" From a pharmacovigilance perspective, TB presents two distinct challenges: Drug-Induced...
ALVigiLance is a dedicated pharmacovigilance platform designed to support the healthcare team in ensuring safer medication use. Our mission is simple yet vital: to provide trusted insights, practical tools, and up-to-date resources that empower healthcare professionals to identify, prevent, and manage adverse drug reactions (ADRs).
Simplified, practical guides on drug safety and monitoring.
Real-world examples to strengthen your clinical decision-making.
Summaries of global drug warnings and regulatory actions.
Strategies for adverse event reporting, risk management, and patient counseling.
To create a proactive community of healthcare providers who champion medication safety and improve patient outcomes through shared knowledge and vigilance.
Medication safety is everyone’s responsibility. Explore, learn, and engage with ALVigiLance — because together, we can reduce risks and save lives.
World Tuberculosis Day 2026 – "Yes! We Can End TB: Led by Countries, Powered by People" From a pharmacovigilance perspective, TB presents two distinct challenges: Drug-Induced...
On March 20, 2026, the U.S. Food and Drug Administration (FDA) issued a significant safety communication requiring the addition of a new warning to all carbidopa/levodopa-containing...
This comprehensive review examines the pharmacovigilance landscape of major GI drug classes, including proton pump inhibitors (PPIs), prokinetic agents (domperidone, metoclopramide), sphingosine-1-phosphate (S1P) receptor modulators, and...
